Ascendis Pharma (ASND)
(Delayed Data from NSDQ)
$193.98 USD
-2.44 (-1.24%)
Updated Sep 23, 2025 04:00 PM ET
After-Market: $193.81 -0.17 (-0.09%) 7:58 PM ET
3-Hold of 5 3
D Value A Growth A Momentum B VGM
Fundamental Charts
About Cash from Investing (Quarterly)
The company's quarterly Cash from Investing value is the sum of the company's current quarter cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
ASND 193.98 -2.44(-1.24%)
Will ASND be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for ASND based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ASND
Wall Street Analysts Believe Ascendis Pharma (ASND) Could Rally 29.83%: Here's is How to Trade
Are Medical Stocks Lagging Ascendis Pharma (ASND) This Year?
ASND: What are Zacks experts saying now?
Zacks Private Portfolio Services
Ascendis Pharma (ASND) Soars 10.4%: Is Further Upside Left in the Stock?
Sage Therapeutics (SAGE) Surges 12.2%: Is This an Indication of Further Gains?
Other News for ASND
Leerink Partners Reaffirms Their Buy Rating on Ascendis Pharma (ASND)
RA CAPITAL MANAGEMENT, L.P. Acquires Significant Stake in LB Pharmaceuticals Inc
Is ASND likely to continue higher? 50 Day Moving Average Support shows up after sliding 0.64%
Wedbush sees no threat to Ascendis’ Yorvipath from competitor data
Wedbush sees no threat to Ascendis' Yorvipath from competitor data